Skip to main content
IRRAS logo

IRRAS — Investor Relations & Filings

Ticker · IRRAS ISIN · SE0008321202 LEI · 549300EKKVQN2J25MJ59 ST Manufacturing
Open in API
Filings indexed 130 across all filing types
Latest filing 2021-11-09 Interim / Quarterly Rep…
Country SE Sweden
Listing ST IRRAS

About IRRAS

https://irras.com/

IRRAS is a commercial-stage medical technology company focused on designing, developing, and commercializing innovative solutions for neurocritical care. The company's core technology addresses challenges in fluid control and management for critically ill patients, particularly those with intracranial bleeding. Its primary product, the IRRAflow system, is an intelligent fluid management device that combines controlled irrigation with drainage to manage fluids and monitor intracranial pressure. The system is designed to improve patient outcomes, reduce complications, and decrease the overall cost of care by providing a new standard for treating brain pathologies.

Recent filings

Filing Released Lang Actions
IRRAS AB publishes Interim Report for the period, January to September 2021
Interim / Quarterly Report Classification · 1% confidence The document is titled 'INTERIM REPORT JANUARY–SEPTEMBER 2021' for IRRAS AB. It contains comprehensive financial statements, including income statements, balance sheet data, cash flow analysis, and detailed management commentary on business performance for the specified interim period. It is not a short announcement or a certification, but the full interim report itself. 9M 2021
2021-11-09 English
IRRAS AB publicerar delårsrapport för januari till september 2021
Interim / Quarterly Report Classification · 1% confidence The document is a 'Delårsrapport' (Interim Report) for IRRAS AB covering the period January–September 2021. It contains comprehensive financial statements, including income statements, balance sheets, cash flow analysis, and detailed management commentary on business performance, regional sales, and operational milestones. It is not an announcement of a report, but the report itself, containing substantive financial data. 9M 2021
2021-11-09 Swedish
IRRAS AB publishes Interim Report for the period, January to June 2021
Interim / Quarterly Report Classification · 1% confidence The document is titled 'INTERIM REPORT JANUARY–JUNE 2021' and contains comprehensive financial statements, including income statements, balance sheet data, cash flow analysis, and detailed management commentary on business performance for the specified period. It is a substantive financial report rather than a mere announcement or certification, fitting the definition of an Interim/Quarterly Report. H1 2021
2021-08-26 English
IRRAS AB publicerar delårsrapport för januari till juni 2021
Interim / Quarterly Report Classification · 1% confidence The document is titled 'DELÅRSRAPPORT JANUARI - JUNI 2021' (Interim Report January - June 2021) for IRRAS AB. It contains comprehensive financial statements, including income statements, balance sheets, cash flow analysis, and management commentary on business performance for the specified period. It is clearly a substantive financial report for a period shorter than a full fiscal year, fitting the definition of an Interim/Quarterly Report. H1 2021
2021-08-26 Swedish
IRRAS erhåller finansiering inom ramen för den alleuropeiska garantifonden
Capital/Financing Update Classification · 1% confidence The document announces that IRRAS has secured a financing agreement of 10 million euros from the European Investment Bank (EIB), supported by the Pan-European Guarantee Fund (EGF). This explicitly details a fundraising or financing activity undertaken by the company. This aligns directly with the definition of 'Capital/Financing Update' (CAP). It is not a full annual report (10-K), an earnings release (ER), or a general regulatory filing (RNS), as it concerns a specific financing event.
2021-07-29 Swedish
IRRAS receives loan financing under European Guarantee Fund
Capital/Financing Update Classification · 1% confidence The document announces that IRRAS has signed a €10 million loan financing agreement with the European Investment Bank (EIB), supported by the European Guarantee Fund (EGF). This is a specific announcement regarding the company securing new debt financing to accelerate product development and clinical trials. This clearly falls under the category of updates on company fundraising, financing activities, or capital structure changes, which corresponds to the 'Capital/Financing Update' definition (Code: CAP). It is not an Annual Report (10-K), an Earnings Release (ER), or a general Regulatory Filing (RNS), as it details a specific financing event.
2021-07-29 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.